---
brand_name: "Brimonidine Tartrate ophthalmic solution, 0.15%"
generic_name: "Brimonidine Tartrate ophthalmic solution, 0.15%"
slug: "brimonidine-tartrate-ophthalmic-solution-0-15-brimonidine-tartrate-ophthalmic-solution-0-15-ophthalmic"
canonical_url: "https://medichelpline.com/drug-index/brimonidine-tartrate-ophthalmic-solution-0-15-brimonidine-tartrate-ophthalmic-solution-0-15-ophthalmic"
content_type: "drug_monograph"
route: "OPHTHALMIC"
drug_class: "General Medications"
fda_updated_at: "2023-03-29T00:00:00.000Z"
license: "Drugs@FDA Public Domain / Informational Use"
---
# Brimonidine Tartrate ophthalmic solution, 0.15% (Brimonidine Tartrate ophthalmic solution, 0.15%)
## Clinical Monograph Metadata
- **Canonical URL:** https://medichelpline.com/drug-index/brimonidine-tartrate-ophthalmic-solution-0-15-brimonidine-tartrate-ophthalmic-solution-0-15-ophthalmic
- **Generic / Active Ingredient:** Brimonidine Tartrate ophthalmic solution, 0.15%
- **Brand Name:** Brimonidine Tartrate ophthalmic solution, 0.15%
- **Administration Route:** OPHTHALMIC
- **Pharmacological Class:** General Medications
- **FDA Data Timestamp:** 2023-03-29T00:00:00.000Z
## Primary Indication & Clinical Use
Marketed solution/ drops containing BRIMONIDINE TARTRATE.
## Monograph Summary

Product profile Marketed solution/ drops containing BRIMONIDINE TARTRATE. Dose form and route SOLUTION/ DROPS · OPHTHALMIC

## Primary Sources & FDA Regulatory Records
- [Drugs@FDA Primary Database](https://www.accessdata.fda.gov/scripts/cder/daf/) (Reference Slug: `brimonidine-tartrate-ophthalmic-solution-0-15-brimonidine-tartrate-ophthalmic-solution-0-15-ophthalmic`)
## Navigation
- [← Back to Drug Index Hub](https://medichelpline.com/drug-index.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.